Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease

Objective. Various markers characterize the complex inflammatory processes seen in chronic inflammatory bowel disease (IBD) including calprotectin, a complex of two S100 proteins, which has been evaluated and validated as a faecal marker of inflammation. However, the systemic and mucosal expression patterns of calprotectin and related S100 proteins are not well characterized in this disease. The objective of this study was to assess serum and mucosal levels of calprotectin, S100A12 and soluble receptor for advanced glycation end products (sRAGE), a putative S100 ligand, in a paediatric population with IBD. Material and methods. Children were enrolled at diagnosis of IBD, along with groups of children without IBD. Standard inflammatory markers and disease activity scores were collated. Calprotectin, S100A12 and sRAGE levels in serum and biopsy culture supernatants were measured by ELISA and tissue distribution of S100 proteins was investigated by immunohistochemistry. Results. Serum and mucosal calprotectin and S100A12 levels were increased in children with IBD as compared with non-IBD controls. Serum calprotectin levels correlated with S100A12 levels and with disease activity scores in children with IBD. sRAGE levels were not increased in IBD. S100A8, S100A9 and S100A12 were abundantly expressed throughout the lamina propria and epithelium in inflamed mucosa. In contrast, these proteins were present in the lamina propria, but not the epithelium, in non-inflamed mucosa. Conclusions. Serum calprotectin and S100A12 are increased in children with IBD and indicate disease activity. Elevated levels of these proteins are present in the colonic mucosa and may contribute to the pathogenesis of IBD. Furthermore, an imbalance between sRAGE and S100A12 may contribute to inflammatory changes present in IBD.

[1]  A. Day,et al.  Fecal S100A12: A novel noninvasive marker in children with Crohn's disease , 2006, Inflammatory bowel diseases.

[2]  Zhong-Gao Xu,et al.  Key Role of Src Kinase in S100B-induced Activation of the Receptor for Advanced Glycation End Products in Vascular Smooth Muscle Cells* , 2006, Journal of Biological Chemistry.

[3]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[4]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[5]  H. Hanai,et al.  Relationship Between Fecal Calprotectin, Intestinal Inflammation, and Peripheral Blood Neutrophils in Patients with Active Ulcerative Colitis , 2004, Digestive Diseases and Sciences.

[6]  D. Foell,et al.  Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. , 2004, Arthritis and rheumatism.

[7]  A. Røseth.  Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. , 2003, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[8]  A. Coleman,et al.  Changing the Conformation State of Cytochrome b558 Initiates NADPH Oxidase Activation , 2003, Journal of Biological Chemistry.

[9]  D. Foell,et al.  Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease , 2003, Gut.

[10]  S. Yui,et al.  Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. , 2003, Biological & pharmaceutical bulletin.

[11]  M. Andrassy,et al.  Central role of RAGE-dependent neointimal expansion in arterial restenosis. , 2003, The Journal of clinical investigation.

[12]  P. Rouleau,et al.  Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.

[13]  S. Kanaoka,et al.  [Clinical significance of faecal calprotectin levels in patients with ulcerative colitis]. , 2003, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[14]  I. Forgacs,et al.  Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. , 2002, Gastroenterology.

[15]  T. Yao.  [Inflammatory bowel diseases]. , 2002, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[16]  N. Hogg,et al.  The S100 Family Heterodimer, MRP-8/14, Binds with High Affinity to Heparin and Heparan Sulfate Glycosaminoglycans on Endothelial Cells* , 2002, The Journal of Biological Chemistry.

[17]  C. Kerkhoff,et al.  Evidence for the Involvement of the Unique C-Tail of S100A9 in the Binding of Arachidonic Acid to the Heterocomplex S100A8/A9 , 2002, Biological chemistry.

[18]  M. Raftery,et al.  Novel Intra- and Inter-molecular Sulfinamide Bonds in S100A8 Produced by Hypochlorite Oxidation* , 2001, The Journal of Biological Chemistry.

[19]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[20]  Rakesh K. Kumar,et al.  Dimeric S100A8 in human neutrophils is diminished after phagocytosis , 2001, Journal of leukocyte biology.

[21]  Tony S. Tao,et al.  Proinflammatory properties of the human S100 protein S100A12 , 2001, Journal of leukocyte biology.

[22]  B. Thjódleifsson,et al.  A simple method for assessing intestinal inflammation in Crohn's disease , 2000, Gut.

[23]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[24]  R. Schmid,et al.  NF-κB/Rel/IκB: Implications in gastrointestinal diseases , 2000 .

[25]  H. Schjønsby,et al.  Improved assay for fecal calprotectin. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[26]  R. Schmid,et al.  NF-kappaB/rel/IkappaB: implications in gastrointestinal diseases. , 2000, Gastroenterology.

[27]  P. Malherbe,et al.  cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.

[28]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[29]  G. D'Haens,et al.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. , 1999, Gastroenterology.

[30]  M. Raftery,et al.  Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8* , 1999, The Journal of Biological Chemistry.

[31]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[32]  C. Geczy,et al.  Induction of the S100 chemotactic protein, CP-10, in murine microvascular endothelial cells by proinflammatory stimuli. , 1997, Blood.

[33]  Sartor Rb.  Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. , 1997 .

[34]  R. Sartor.  Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. , 1997, The American journal of gastroenterology.

[35]  P. Kenny,et al.  Functional chemotactic factor CP-10 and MRP-14 are abundant in murine abscesses , 1996, Infection and immunity.

[36]  J. Brun,et al.  Effects of calprotectin in avridine‐induced arthritis , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[37]  K. Schmid,et al.  Immunohistochemical distribution and serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. , 1995, Digestion.

[38]  R. Jonsson,et al.  Sjögren's syndrome in inflammatory rheumatic diseases: analysis of the leukocyte protein calprotectin in plasma and saliva. , 1994, Scandinavian journal of rheumatology.

[39]  Henderson Ar,et al.  Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. , 1993 .

[40]  A R Henderson,et al.  Assessing Test Accuracy and its Clinical Consequences: A Primer for Receiver Operating Characteristic Curve Analysis , 1993, Annals of clinical biochemistry.

[41]  C. Bengis-Garber,et al.  Calcium‐binding myeloid protein (P8,14) is phosphorylated in fMet‐Leu‐Phe‐stimulated neutrophils , 1993, Journal of leukocyte biology.

[42]  E. Vollmer,et al.  MRP8 and MRP14, S-100-like proteins associated with myeloid differentiation, are translocated to plasma membrane and intermediate filaments in a calcium-dependent manner. , 1993, Blood.

[43]  R. Christensen,et al.  The distribution of the antimicrobial protein, calprotectin, in normal oral keratinocytes. , 1992, Archives of oral biology.

[44]  A. Griffiths,et al.  Relationship of Common Laboratory Parameters to the Activity of Crohn's Disease in Children , 1992, Journal of pediatric gastroenterology and nutrition.

[45]  P. Mowinckel,et al.  The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. , 1991, The Journal of rheumatology.

[46]  E. Lingaas,et al.  Antimicrobial actions of calcium binding leucocyte L1 protein, calprotectin , 1990, The Lancet.

[47]  F. Collart,et al.  A protein containing the cystic fibrosis antigen is an inhibitor of protein kinases. , 1989, The Journal of biological chemistry.

[48]  P. Brandtzaeg,et al.  Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. I. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. , 1987, American journal of clinical pathology.